Harmony Biosciences Holdings, Inc. filed a Form 8-K/A on October 30, 2026, amending its October 13, 2026 current report to provide the compensation and separation details for outgoing CEO Jeffrey M. Dayno, M.D., and incoming CEO Peter Anastasiou, which had not been finalized at the time of the original filing.

Key Highlights

  • CEO transition date: Jeffrey M. Dayno, M.D., will retire as President and CEO and step down as a Class I director effective December 31, 2026, at 11:59 p.m. Eastern Time, according to the filing.
  • Successor appointment: Peter Anastasiou, currently Senior Executive Vice President and Chief Operating Officer, has been appointed President and CEO and Class I director effective January 1, 2027, at 12:00 a.m. Eastern Time.
  • Anastasiou base salary: The amended employment agreement sets his annual base salary at $725,000, effective as of the appointment date.
  • Anastasiou target bonus: Beginning with calendar year 2027, his target annual bonus opportunity will equal 75% of his annual base salary.
  • Anastasiou equity grants: Within 30 days of his appointment, he is eligible to receive an option award with an aggregate grant date fair value of $1,750,000 and restricted stock units with an aggregate grant date fair value of $750,000.
  • Dayno consulting role: Under the Separation and Consulting Agreement dated October 29, 2026, Dr. Dayno will provide consulting services through January 31, 2028, at $500 per hour, with continued vesting of equity awards during that period.
  • Dayno severance basis: The filing states Dr. Dayno is entitled to severance payments and benefits "in accordance with his employment agreement and award agreements, in exchange for a release of claims."

Leadership Transition Terms at Harmony Biosciences: Dayno Separation and Anastasiou Employment Details

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) filed the amendment because the compensation arrangements for both Dr. Dayno and Mr. Anastasiou had not been determined when the original Form 8-K was filed on October 13, 2026. The company disclosed that on October 29, 2026, it entered into a Separation and Consulting Agreement with Dr. Dayno and an Amended and Restated Executive Employment Agreement with Mr. Anastasiou, with both agreements involving the company, Harmony Biosciences, LLC, and Harmony Biosciences Management, Inc., as applicable.

Under the Separation and Consulting Agreement, Dr. Dayno's severance payments and benefits are governed by his existing employment agreement and award agreements, conditioned on a release of claims and continued compliance with the Separation Agreement and any restrictive covenants. During his consulting period through January 31, 2028, Dr. Dayno will receive $500 per hour for consulting services and continued vesting of any equity or equity-based awards he holds as of the Resignation Effective Date, with full vesting triggered upon a change in control during that period, according to the filing.

For Mr. Anastasiou, the A&R Employment Agreement sets out equity vesting terms under which 25% of each award vests on the first anniversary of the Appointment Effective Date, with the remaining 75% vesting quarterly through the fourth anniversary, subject to continued service. The filing notes that the descriptions of both agreements are "not complete and is subject to and qualified in its entirety" by the full text of each agreement, filed as Exhibits 10.1 and 10.2 respectively.

What Was Disclosed

The amendment disclosed the specific compensation, consulting, and separation terms for Dr. Dayno and Mr. Anastasiou in connection with the CEO leadership change, including salary, bonus target, equity grant values, consulting rate, and vesting schedules, none of which were available in the original filing.